Appointments

Dr Kostrzewski originally joined the company in 2015 and was appointed to director of biology in 2018, where he was responsible for all collaborative research projectsandbiologicalassaydevelopment. He was promoted again in 2021 to vice presidentofscienceandtechnology,where he took charge of all contract research services and technical activities.

He stated: “Having joined the CN Bio team over eight years ago, I’ve had the greatopportunitytobeatthecutting-edge of this rapidly evolving industry and witness research and legislations evolve as the potential of OOC technology is realised. As the next stage in my career, it is a privilege to be promoted from within to support the Company as CSO. Our reputation is a testament to the team we have built and its extensive background in bioengineering and drug discovery, and I very much look forward to progressing all the opportunities we have in the pipeline to advance the future of drug development.”

Before joining the team at CN Bio, Dr KostrzewskiworkedintheDepartmentof Life Sciences at Imperial College London where he studied stem cell differentiation and immune cell development. He also worked in biopharmaceutical drug development at GSK, and currently holds three degrees in Cell and Molecular Biology.

As CSO at CN Bio, he will now work closely with key industry stakeholders, such as the US Food and Drug Administration(FDA),inordertovalidate the development of the company’s OOC technology. He will also be responsible for ensuring all the latest technological advances are incorporated into the company’s bioengineered solutions.

Dr Paul Brooks, CEO of CN Bio, stated: “Tom is an asset to our team, his technical expertise paired with his insight and connections within the industry have been invaluable to CN Bio’s development and solidifying our reputation as leading providers of advanced OOC solutions. It has been a pivotal year for the Company’s growth, particularly to build and strengthen our senior leadership team – with Tom as our first CSO we are in a strong position to drive our commercial strategy forward, providing the deep expertise to better understand human physiology, disease and the effectiveness of new drugs.”